山东大学学报 (医学版) ›› 2024, Vol. 62 ›› Issue (7): 56-61.doi: 10.6040/j.issn.1671-7554.0.2024.0587
张学宇1,张学海1,孙文青2,刘晗3,姜金波4,刘寒1,李远1,陈晓梅1
中图分类号:
| [1] Hoenigl M, Seidel D, Sprute R, et al. COVID-19-associated fungal infections[J]. Nat Microbiol, 2022, 7(8): 1127-1140. [2] Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic infections: a snapshot on the current reports[J]. Clin Ex Med, 2022, 22(3): 327-346. [3] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention[J]. JAMA, 2020, 323(13): 1239-1242. [4] Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance[J]. Lancet Infect Dis, 2021, 21(6): e149-e162. [5] Feys S, Lagrou K, Lauwers HM, et al. High burden of COVID-19-associated pulmonary aspergillosis in severely immunocompromised patients requiring mechanical ventilation[J]. Clin Infect Dis, 2024, 78(2): 361-370. [6] Apostolopoulou A, Esquer Garrigos Z, Vijayvargiya P, et al. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature[J]. Diagnostics(Basel), 2020, 10(10): 807. doi: 10.3390/diagnostics10100807. [7] Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis(CAPA)—from immunology to treatment[J]. J Fungi(Basel), 2020, 6(2): 91. doi: 10.3390/jof6020091. [8] Dellière S, Dudoignon E, Fodil S, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort[J]. Clin Microbiol Infect, 2021, 27(5): 790.e1-790.e5. [9] Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-associated pulmonary aspergillosis, March-August 2020[J]. Emerg Infect Dis, 2021, 27(4):1077-1086. [10] Hashim Z, Nath A, Khan A, et al. Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: a meta-analysis of 21 studies and 5174 patients[J]. Mycoses, 2023, 66(11): 941-952. [11] Leistner R, Schroeter L, Adam T, et al. Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients[J]. Crit Care, 2022, 26(1): 30. doi: 10.1186/s13054-022-03902-8. [12] WHO Rapid Evidence Appraisal for COVID-19 Therapies(REACT)Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a Meta-analysis[J]. JAMA, 2020, 324(13): 1330-1341. [13] Alexander BD, Lamoth F, Heussel CP, et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC[J]. Clin Infect Dis, 2021, 72(Suppl 2): S79-S88. [14] Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance[J]. Lancet Infect Dis, 2021, 21(6): e149-e162. [15] Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments[J]. Lancet Infect Dis, 2004, 4(12): 725-738. [16] Orenstein JM, Dieterich DT. The histopathology of 103 consecutive colonoscopy biopsies from 82 symptomatic patients with acquired immunodeficiency syndrome: original and look-back diagnoses[J]. Arch Pathol Lab Med, 2001, 125(8): 1042-1046. [17] He J, Liu Y, Wang Z, et al. Colonoscopy in the diagnosis of intestinal graft versus host disease and cytomegalovirus enteritis following allogeneic haematopoietic stem cell transplantation[J]. Chin Med J(Engl), 2008, 121(14): 1285-1289. [18] Wetwittayakhlang P, Rujeerapaiboon N, Wetwittayakhlung P, et al. Clinical features, endoscopic findings, and predictive factors for mortality in tissue-invasive gastrointestinal cytomegalovirus disease between immunocompetent and immunocompromised patients[J]. Gastroenterol Res Pract, 2021, 2021: 8886525. doi: 10.1155/2021/8886525. [19] Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13512. doi: 10.1111/ctr.13512. [20] Yeh PJ, Wu RC, Chen CL, et al. Cytomegalovirus diseases of the gastrointestinal tract in immunocompetent patients: a narrative review[J]. Viruses, 2024, 16(3): 346. doi: 10.3390/v16030346. [21] Kreitmann L, Helms J, Martin-Loeches I, et al. ICU-acquired infections in immunocompromised patients[J]. Intensive Care Med, 2024, 50(3): 332-349. [22] Gatto I, Biagioni E, Coloretti I, et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality[J]. Intensive Care Med, 2022, 48(6): 706-713. [23] Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis[J]. Lancet Microbe, 2021, 2(1): e13-e22. [24] Lindahl AL, Ahava MJ, Haukipää M, et al. Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report[J]. Infect Dis(Lond), 2023, 55(8): 585-589. [25] Chan M, Linn MMN, OHagan T, et al. Persistent SARS-CoV-2 PCR positivity despite anti-viral treatment in immunodeficient patients[J]. Lancet Infect Dis, 2023, 43(6): 1083-1092. [26] Machkovech HM, Hahn AM, Garonzik Wang J, et al. Persistent SARS-CoV-2 infection: significance and implications[J]. Lancet Infect Dis, 2024, 24(7): e453-e462. [27] 骆琼珍, 徐文帅, 高博, 等.新型冠状病毒感染患者核酸长期阳性的相关因素与核酸转阴的特点分析[J]. 中华医学杂志,2024, 104(5): 385-388. LUO Qiongzhen, XU Wenshuai, GAO Bo, et al. Analysis of the correlative factors of long-term positive nucleic acid and the characteristics of nucleic acid conversion in novel coronavirus infected patients[J]. National Medical Journal of China, 2024, 104(5): 385-388. [28] Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID[J]. J Clin Invest, 133(3): e163669. doi: 10.1172/JCI163669. |
| [1] | 李波波 李道堂 刘曙光 王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61. |
| [2] | 徐平 于国放 李霞. 不同类型甲状腺上动脉PSV对Graves病与桥本氏甲状腺炎鉴别诊断的价值[J]. 山东大学学报(医学版), 2209, 47(6): 62-64. |
| [3] | 王欣，邢春燕，杨艳平. 血清磷酸丙酮酸水合酶检测对诊断侵袭性白念珠菌感染的临床价值[J]. 山东大学学报(医学版), 2209, 47(6): 92-94. |
| [4] | 巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-. |
| [5] | 山东省医学会心电学分会山东省医学伦理学学会心电学分会. 心电图报告规范化书写专家共识(2026)[J]. 山东大学学报 (医学版), 2026, 64(4): 1-7. |
| [6] | 孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62. |
| [7] | 林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124. |
| [8] | 樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23. |
| [9] | 中国医师协会骨科医师分会智能骨科学组,中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组. 人工智能脊柱退变影像学测量位点与标注专家共识(2025)[J]. 山东大学学报 (医学版), 2026, 64(2): 1-10. |
| [10] | 李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76. |
| [11] | 罗淇,王霞,姜孟. 脑功能网络分析在失语症诊疗中的应用:病理机制分析、临床诊断与疗效评价[J]. 山东大学学报 (医学版), 2025, 63(8): 111-126. |
| [12] | 河南省生物医学工程学会立体心电图专业委员会,中国医药教育协会心电学专业委员会,山东中医药学会心电学专业委员会,青岛市医学会心电生理与起搏专科分会,全国医药技术市场协会远程心脏专业委员会. 心电向量图诊断标准规范化专家共识(2025)[J]. 山东大学学报 (医学版), 2025, 63(7): 1-10. |
| [13] | 刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74. |
| [14] | 葛雪,赵红艳. 疱疹病毒感染对重症肺炎患者临床预后及呼吸道微生态的影响[J]. 山东大学学报 (医学版), 2025, 63(6): 27-37. |
| [15] | 祝永才,谢艳,齐秋晨,李培龙,王传新,杜鲁涛. 基于外周血单个核细胞ATM基因甲基化的联合模型在胰腺癌早期诊断中的价值[J]. 山东大学学报 (医学版), 2025, 63(6): 78-88. |
|
||
